cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Pepgen Inc
1 own
1 watching
Current Price
$11.39
$0.86
(8.12%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
95.16M
52-Week High
52-Week High
17.51000
52-Week Low
52-Week Low
3.72000
Average Volume
Average Volume
0.05M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization95.16M
icon52-Week High17.51000
icon52-Week Low3.72000
iconAverage Volume0.05M
iconDividend Yield--
iconP/E Ratio--
What does the Pepgen Inc do?
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company s lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Pepgen Inc make?
News & Events about Pepgen Inc.
GuruFocus
10 months ago
Related Stocks: PEPG...
Globe Newswire
1 year ago
- In NHP, four monthly doses of 20 mg/kg of PGN-EDO51 resulted in 34.9% exon skipped transcripts in biceps; a 14-fold increase over the 2.5% exon 51 skipped transcripts observed after a single dose - Following on the EDO51 Phase 1 study, we anticipate initiating in the first half of 2023 the ...
Globe Newswire
1 year ago
BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases,will report its fourth quarter and ...
Globe Newswire
1 year ago
BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases,today announced that it will present ...
Globe Newswire
1 year ago
BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, ...
Frequently Asked Questions
Frequently Asked Questions
What is Pepgen Inc share price today?
plus_minus_icon
Can Indians buy Pepgen Inc shares?
plus_minus_icon
How can I buy Pepgen Inc shares from India?
plus_minus_icon
Can Fractional shares of Pepgen Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Pepgen Inc stocks?
plus_minus_icon
What is today’s traded volume of Pepgen Inc?
plus_minus_icon
What is today’s market capitalisation of Pepgen Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Pepgen Inc?
plus_minus_icon
What percentage is Pepgen Inc down from its 52-Week High?
plus_minus_icon
What percentage is Pepgen Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$11.39
$0.86
(8.12%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00